Aethlon Medical Announces Zika Virus Data

SAN DIEGO, Aug. 11, 2016  -- Aethlon Medical, Inc. (AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, announced today that its researchers have completed in vitro studies that demonstrate the rapid capture of Zika virus by the Aethlon Hemopurifier®. The Hemopurifier® is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies.  At present, the immunotherapeutic technology is being advanced through an FDA approved human feasibility study.  The Zika studies, which were conducted with small-scale versions of the Hemopurifier®, demonstrated a 95% clearance of Zika virus from cell culture fluid in 5.5 hours and an approximate 50% clearance of Zika from human blood serum in 5 hours. 
The studies were conducted with the Zika viral strain that has recently spread from South America to ravage Puerto Rico and likely responsible for the first wave of infections that have begun to occur in the United States.  
Read more: Aethlon Medical Inc ( AEMD )

Cesca Therapeutics Announces Promising Results From 40-Month Follow-Up of Patients Enrolled in Critical Limb Ischemia Feasibility Study

RANCHO CORDOVA, Calif., Aug. 03, 2016  -- Cesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, today announced 40-month follow-up results for a number of patients that participated in the Company’s earlier feasibility study using Cesca’s proprietary SurgWerks™ system for the treatment of late stage, “no option” critical limb ischemia (CLI).
The feasibility study was conducted in 2011 at Fortis Escorts Heart Institute in New Delhi, India, where seventeen patients with late stage CLI, all of whom had exhausted available surgical options short of a major limb amputation, were treated with autologous bone marrow derived stem cells. The 40-month follow-up was approved as a protocol amendment by the local Institutional Ethics Committee, specifically to measure longer-term safety and efficacy end-points related to limb salvage, disease progression, and quality of life improvement.
Read more: Cesca Therapeutics Inc ( KOOL )

TransEnterix, Inc. Announces First Sale of ALF-XⓇ Surgical Robotic System

TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced the first global sale of its ALF-XⓇ Surgical Robotic System to Humanitas Hospital in Milan, Italy.
“We are pleased to announce the first global sale of our ALF-X System,” said Todd M. Pope, President and CEO of TransEnterix. “Humanitas is an outstanding academic hospital with a respected multi-specialty surgical program. The ALF-X enables an enhanced surgical program through the use of advanced robotic technology with responsible procedural economics.”
Read more: TransEnterix Inc ( TRXC )

Bovie Medical Corporation Reports Second Quarter and First Half 2016 Results

CLEARWATER, Fla. -- Bovie Medical Corporation (BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced results for the second quarter ended June 30, 2016.
Management Comments
“We continued to execute well in the second quarter, achieving double-digit revenue growth that reflected strong demand across our three product categories,” said Robert L. Gershon, Chief Executive Officer. “This broad-based growth benefited from Bovie’s brand recognition for quality product development and the solid foundation we established in 2015 across our sales, manufacturing and R&D platforms. Our core products business continued to grow at a steady pace; as anticipated, OEM operations benefited from new contracts signed late last year; and the strong performance of J-Plasma® was driven by a more favorable balance between generator and hand piece sales and increased product usage.”
Read more: Bovie Medical Corporation ( BVX )

Medigus Receives First Purchase Order From The Johns Hopkins Hospital for Its MUSE™ System

OMER, Israel, July 27, 2016 -- Medigus Ltd. (MDGS) (MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that Johns Hopkins Hospital, an integrated global health enterprise and one of the leading health care systems in the United States, has provided an initial purchase order (PO) for the MUSE™ system. The PO covers the cost of a MUSE system console and endoscopic device, which will be available for use on eligible patients suffering from GERD.
The Medigus Ultrasonic Surgical Endostapler, or MUSE system, is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. The device is equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication — the procedure intended to treat the anatomical cause of gastroesophageal reflux disease (GERD).
Read more: Medigus Ltd ( MDGS )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker